836 related articles for article (PubMed ID: 10860194)
1. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
3. Direct vascular effects of HMG-CoA reductase inhibitors.
Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
[TBL] [Abstract][Full Text] [Related]
4. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Corpataux JM; Naik J; Porter KE; London NJ
J Surg Res; 2005 Nov; 129(1):52-6. PubMed ID: 16087194
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
6. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
7. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
9. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
[TBL] [Abstract][Full Text] [Related]
10. Toward a role for statins in immunomodulation.
Mach F
Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
[TBL] [Abstract][Full Text] [Related]
11. Non-lipid-related effects of statins.
Bellosta S; Ferri N; Bernini F; Paoletti R; Corsini A
Ann Med; 2000 Apr; 32(3):164-76. PubMed ID: 10821323
[TBL] [Abstract][Full Text] [Related]
12. Effect of statins on fibroblasts from human nasal polyps and turbinates.
Folli C; Descalzi D; Bertolini S; Riccio AM; Scordamaglia F; Gamalero C; Barbieri M; Passalacqua G; Canonica GW
Eur Ann Allergy Clin Immunol; 2008 Nov; 40(3):84-9. PubMed ID: 19334372
[TBL] [Abstract][Full Text] [Related]
13. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Wong WW; Tan MM; Xia Z; Dimitroulakos J; Minden MD; Penn LZ
Clin Cancer Res; 2001 Jul; 7(7):2067-75. PubMed ID: 11448925
[TBL] [Abstract][Full Text] [Related]
14. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
15. Statins effect on smooth muscle cell proliferation.
Bellosta S; Arnaboldi L; Gerosa L; Canavesi M; Parente R; Baetta R; Paoletti R; Corsini A
Semin Vasc Med; 2004 Nov; 4(4):347-56. PubMed ID: 15861311
[TBL] [Abstract][Full Text] [Related]
16. Effect of statins on the viability of macrophages and smooth muscle cells.
Croons V; De Meyer I; Houten SM; Martinet W; Bult H; Herman AG; De Meyer GR
J Cardiovasc Pharmacol; 2010 Mar; 55(3):269-75. PubMed ID: 20051876
[TBL] [Abstract][Full Text] [Related]
17. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Rodríguez C; Alcudia JF; Martínez-González J; Guadall A; Raposo B; Sánchez-Gómez S; Badimon L
Cardiovasc Res; 2009 Aug; 83(3):595-603. PubMed ID: 19406911
[TBL] [Abstract][Full Text] [Related]
18. [The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Raiteri M; Arnaboldi L; Quarato P; Paoletti R; Fumagalli R; Corsini A
Ann Ital Med Int; 1995 Oct; 10 Suppl():35S-42S. PubMed ID: 8562263
[TBL] [Abstract][Full Text] [Related]
19. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Kubota T; Fujisaki K; Itoh Y; Yano T; Sendo T; Oishi R
Biochem Pharmacol; 2004 Jun; 67(12):2175-86. PubMed ID: 15163549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
